Invention Grant
US09334288B2 Selective β-glucuronidase inhibitors as a treatment for side effects of camptothecin antineoplastic agents
有权
选择性 - 葡萄糖醛酸苷酶抑制剂作为喜树碱抗肿瘤剂副作用的治疗
- Patent Title: Selective β-glucuronidase inhibitors as a treatment for side effects of camptothecin antineoplastic agents
- Patent Title (中): 选择性 - 葡萄糖醛酸苷酶抑制剂作为喜树碱抗肿瘤剂副作用的治疗
-
Application No.: US14033920Application Date: 2013-09-23
-
Publication No.: US09334288B2Publication Date: 2016-05-10
- Inventor: Matthew R. Redinbo
- Applicant: The University of North Carolina at Chapel Hill
- Applicant Address: US NC Chapel Hill
- Assignee: The University of North Carolina at Chapel Hill
- Current Assignee: The University of North Carolina at Chapel Hill
- Current Assignee Address: US NC Chapel Hill
- Agency: Alston & Bird LLP
- Main IPC: A61K31/335
- IPC: A61K31/335 ; A61K31/00 ; A61K31/38 ; A61K31/435 ; A61K45/06 ; A61K31/381 ; A61K31/4704 ; A61K31/4745 ; A61K31/496 ; A61K31/519 ; A61K31/5377 ; C07D495/14 ; C07D215/227 ; C07D317/50 ; C07D333/38 ; C07D487/04 ; C07D495/04

Abstract:
Compounds, compositions and methods are provided that comprise selective β-glucuronidase inhibitors for both aerobic and anaerobic bacteria, especially enteric bacteria normally associated with the gastrointestinal tract. The compounds, compositions and methods can be for inhibiting bacterial β-glucuronidase and for improving efficacy of camptothecin-derived antineoplastic agents or glucuronidase-substrate agents or compounds by attenuating the side effects caused by reactivation by bacterial β-glucuronidases of glucuronidated metabolites of camptothecin-derived antineoplasatic agents or glucuronidase-substrate agents or compounds.
Public/Granted literature
Information query